Table 4. Median Survival of Breast Cancer Patients by Extent of Systemic Metastatic Disease.
| Subtype | Type of Metastasis | Survival, Median (IQR), mo | |
|---|---|---|---|
| Extracranial Systemic Disease Only | Extracranial Systemic Disease and Brain Metastases | ||
| HR+/HER2− | Lung | 42.0 (15.0-NR) | 18.0 (2.0-36.0) |
| Liver | 30.0 (10.0-NR) | 9.0 (2.0-18.0) | |
| Bone | 39.0 (21.0-NR) | 15.0 (6.0-31.0) | |
| 2 of 3 | 28.0 (11.0-NR) | 16.0 (5.0-37.0) | |
| All 3 | 18.0 (6.0-39.0) | 12.0 (4.0-NR) | |
| HR+/HER2+ | Lung | NR (21.0-NR) | 18.0 (10.0-NR) |
| Liver | NR (19.0-NR) | NR (NR-NR) | |
| Bone | 46.0 (25.0-NR) | 29.0 (12.0-NR) | |
| 2 of 3 | 34.0 (16.0-NR) | 17.0 (4.0-NR) | |
| All 3 | 24.0 (6.0-NR) | 12.0 (6.0-NR) | |
| HR−/HER2+ | Lung | 25.0 (14.0-NR) | 9.0 (4.0-17.0) |
| Liver | NR (12.0-NR) | 6.0 (4.0-6.0) | |
| Bone | NR (13.0-NR) | NR (8.0-NR) | |
| 2 of 3 | 28.0 (10.0-NR) | 9.0 (5.0-NR) | |
| All 3 | 19.0 (8.0-NR) | 11.0 (3.0-16.0) | |
| Triple-negative | Lung | 14.0 (5.0-29.0) | 7.0 (2.0-9.0) |
| Liver | 14.0 (5.0-27.0) | NR (3.0-NR) | |
| Bone | 14.0 (5.0-32.0) | 11.0 (4.0-15.0) | |
| 2 of 3 | 10.0 (5.0-17.0) | 5.0 (3.0-7.0) | |
| All 3 | 5.0 (2.0-13.0) | 5.0 (1.0-12.0) | |
| Unknown | Lung | 16.0 (4.0-38.0) | 9.0 (2.0-20.0) |
| Liver | 18.0 (4.0-NR) | 1.0 (1.0-9.0) | |
| Bone | 28.0 (8.0-47.0) | 12.0 (2.0-19.0) | |
| 2 of 3 | 15.0 (5.0-33.0) | 12.0 (1.0-18.0) | |
| All 3 | 12.0 (3.0-28.0) | 2.0 (1.0-7.0) | |
| All subtypes | Lung | 25.0 (10.0-NR) | 8.0 (2.0-19.0) |
| Liver | 29.0 (9.0-NR) | 9.0 (3.0-27.0) | |
| Bone | 37.0 (17.0-NR) | 14.0 (4.0-35.0) | |
| 2 of 3 | 24.0 (9.0-NR) | 10.0 (3.0-34.0) | |
| All 3 | 16.0 (5.0-35.0) | 7.0 (2.0-27.0) | |
Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IQR, interquartile range; NR, not reached. + Denotes positive; − denotes negative.